Ezra Launches 3T MRI/CT Combination for Full-Body Scans
The Ezra Blueprint scan reportedly includes quantitative brain measurements, coronary calcium scoring (CAC) and a full-body MRI that provides screening for over 500 conditions.
Offering a combination of 3T magnetic resonance imaging (MRI) and computed tomography (CT) that can provide fatty liver assessment, lung cancer screening and aneurysm detection with two hour-long appointments, Ezra has launched the Ezra Blueprint scan.
The Ezra Blueprint scan reportedly includes neurodegenerative assessment with brain MRI, artificial intelligence (AI)-powered quantification of subcutaneous fat and MRI angiography for possible diagnosis of brain aneurysm and carotid artery disease, according to Ezra, the developer of the Ezra Blueprint.
The newly launched Ezra Blueprint scan reportedly combines 3T MRI and CT for full-body scanning that facilitates screening for over 500 conditions. (Images courtesy of Ezra.)
Other features included in the Ezra Blueprint are high-resolution imaging of knee and hip joints, CT-based coronary calcium scoring (CAC) and full-body MRI that enables screening of over 500 conditions, according to Ezra.
After two 60-minute appointments to complete Ezra Blueprint scanning, Ezra said patients will subsequently receive a detailed radiology report and a consultation review by medical providers associated with Ezra.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
